AKT1 and nonpapillary renal cell carcinoma: In line with these studies, the miR-21-silencing strategy is of potential interest in ccRCC treatment since PTEN, a potent inhibitor of the PI3K/AKT pathway, and PPAR-α are direct targets of miR-21.